Researchers at The University of Texas MD Anderson Cancer Center have discovered how an aggressive form of prostate cancer called double-negative prostate cancer (DNPC) metastasizes by evading the the immune system. The investigators also reported on the pre-clinical development of a new therapy, which, when given in combination with existing immunotherapies, appears to stop and even reverse metastasis in mouse models.
A Penn study of more than 150,000 men with prostate cancer shows androgen deprivation therapy was associated with a higher likelihood of developing dementia when compared to patients who were not exposed to the treatment.
New research that uncovers the mechanism behind the newest generation of cancer drugs is opening the door for better targeted therapy. PARP inhibitors are molecular targeted cancer drugs used to treat women with ovarian cancer who have the BRCA1 and BRCA2 gene mutations. The drugs are showing promise in late-stage clinical trials for breast cancer, prostate cancer and pancreatic cancer.
Data for 154,089 older men diagnosed with prostate cancer were used to analyze the association between androgen deprivation therapy, a hormone-suppressing therapy used to treat prostate cancer, and subsequent diagnosis of Alzheimer disease or dementia. Of the men, 62,330 (average age 76) received androgen deprivation therapy within two years of being diagnosed with prostate cancer and 91,759 men (average age 74) didn't have such treatment.
Prostate cancer represents a major health challenge and there is currently no effective treatment once it has advanced to the aggressive, metastatic stage. A new has revealed a key cellular mechanism that contributes to aggressive prostate cancer, and supporting a new clinical trial.
A team of researchers from UCLA and the University of Toronto have identified a new biomarker found in urine that can help detect aggressive prostate cancer, potentially saving hundreds of thousands of men each year from undergoing unnecessary surgeries and radiotherapy treatments.
Treating prostate cancer with higher doses of proton therapy over a shorter amount of time leads to similar outcomes when compared to standard dose levels and treatments and is safe for patients.
Researchers have developed an improved technique for using magnetic nanoclusters to kill hard-to-reach tumors.
In a study with mice, a gene therapy developed in Brazil kills cancer cells and avoids adverse side effects when combined with chemotherapy.
A new study from researchers at the University of Michigan Rogel Cancer Center finds that the gene FOXA1 overrides normal biology in three different ways to drive prostate cancer. They refer to the three classes as FAST, FURIOUS, and LOUD to reflect their unique features.